# ADMA catalysts: ADMA BIOLOGICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/adma/catalysts

> ADMA BIOLOGICS, INC. (ADMA) has no upcoming catalysts in this calendar. The latest recorded is the ADMA BIOLOGICS, INC. earnings report, November 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ADMA BIOLOGICS, INC. |
| Ticker | ADMA (Nasdaq) |
| SEC CIK | 1368514 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/adma |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 12, 2023 | [Expansion FDA approval](https://sec-api.dev/pdufa/expansion) | ADMA |  | completed, approved | "On December 12, 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the U.S. to now include the pediatric setting for those two years of age and older." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036125009257/ef20038923_10k.htm)) |
| 2025 | [SG-001 interim data readout](https://sec-api.dev/pdufa/sg-001) | ADMA |  | scheduled | "SG-001 Program on Track for Initial Data Readout in 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/ef20053140_ex99-1.htm)) |
| March 3, 2025 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036125006745/ef20044777_ex99-1.htm)) |
| April 28, 2025 | [SG-001 FDA approval](https://sec-api.dev/pdufa/sg-001) | ADMA |  | completed, approved | "On April 28, 2025, ADMA Biologics, Inc., a Delaware corporation (the "Company"), issued a press release announcing that it has received U.S. Food and Drug Administration ("FDA") approval of the Company's innovative production yield enhancement process." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036125015881/ef20048038_8k.htm)) |
| May 5, 2025 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036125017704/ef20048524_ex99-1.htm)) |
| Jun 2025 | [Expansion NDA/BLA submission](https://sec-api.dev/pdufa/expansion) | ADMA |  | completed | "In June 2025, we filed our supplemental Biologics License Application ("sBLA") for the expansion of ASCENIV's label to include the pediatric setting for patients who are two years and older and we anticipate potential FDA approval of the sBLA in the first half of fiscal year 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/ef20059416_10-k.htm)) |
| August 5, 2025 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/ef20053140_ex99-1.htm)) |
| November 5, 2025 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036125040539/ef20058354_ex99-1.htm)) |
| February 20, 2026 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036126006781/ef20066393_ex99-1.htm)) |
| May 4, 2026 | [Expansion label expansion decision](https://sec-api.dev/pdufa/expansion) | ADMA |  | completed, approved | "On May 4, 2026, ADMA Biologics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved the Company's label expansion supplemental Biologics License Application for ASCENIVTM to include pediatric immune compromised patients two years of age and older." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036126018667/ef20072196_8k.htm)) |
| May 6, 2026 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/ef20072554_ex99-1.htm)) |
| August 5, 2026 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/ef20079311_ex99-1.htm)) |
| November 4, 2026 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036126041959/ef20084542_ex99-1.htm)) |

## Drugs

- [Expansion](https://sec-api.dev/pdufa/expansion): 
- [SG-001](https://sec-api.dev/pdufa/sg-001): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/adma/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ADMA catalysts: ADMA BIOLOGICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/adma/catalysts

```bibtex
@misc{secapidev_companies_adma_catalysts_20261116,
  title        = {ADMA catalysts: ADMA BIOLOGICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/adma/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_adma_catalysts_20261116","title":"ADMA catalysts: ADMA BIOLOGICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/adma/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
